1.Epidemiological studies on familial aggregation of selected cancers.
Jhin Oh LEE ; Soo Yong CHOI ; Yun Sang SHIM
Journal of the Korean Cancer Association 1991;23(3):658-666
No abstract available.
Epidemiologic Studies*
2.A case of isolated ACTH deficiency.
Tae Yong SON ; Myung Shik LEE ; Jhin Oh LEE ; Tae Woong KANG
Journal of Korean Society of Endocrinology 1991;6(4):367-370
No abstract available.
Adrenocorticotropic Hormone*
3.Abberant expression of HLA-DR antigen in thyroid cancer.
Myung Shik LEE ; Kyung Ja CHO ; Weon Seon HONG ; Chang Min KIM ; Jhin Oh LEE ; Tae Woong KANG
Korean Journal of Immunology 1991;13(2):195-199
No abstract available.
HLA-DR Antigens*
;
Thyroid Gland*
;
Thyroid Neoplasms*
4.A Phase 2 Trial of EPOCH (Etoposide, Vincristine, Doxorubicin, Cyclophophamide and Prednisolone) Chemotherapy for Previously Treated Non - Hodgkin's Lymphoma.
Baek Yeol RYOO ; Tae You KIM ; Young Hyuk IM ; Jhin Oh LEE ; Taik Koo YUN ; Keun Chil PARK
Journal of the Korean Cancer Association 1998;30(1):127-136
PURPOSE: As a new strategy to modulate drug resistance in the treatment of relapsed or refractory non-Hodgkin's lymphoma(NHL), continuos infusion of drugs has been incorporated into the chemotherapy. We conducted a phase II study to determine the activity and safety of EPOCH (etoposide, vincristine, doxorubicin, cyclophosphamide, prednisolone) chemotherapy, in which the natursl products are administered as a continuous infusion, for previously treated NHL's of intermediate grade. MATERIALS AND METHODS: EPOCH chemotherapy (etoposide 50 mg/m2/day 24 hour- continuous infusion, days 1~4, vincristine 0.4 mg/m2/day 24 hour-continuous infusion, days 1~4, doxorubicin 10 mg/m2/day 24 hour-continuous infusion, days 1~4, cyclophosphamide 750 mg/m2 i.v., day 5, prednisolone 60 mg/m2/day p.o. days 1-5) was given to eligible patients every 3 weeks and we assessed response and toxicity of the regimen. RESULTS: Between June 1993 and December 1995, total 56 patients entered this trial and 49 were evaluable. The complete response rate was 41%(95% C.I.: 27-55%). After follow up of 9~50(median 38) months, progression free survival was 0~39+(median 7) months and the overall survival was 1~44+(median 14) months. The prognostic factor analyses showed that B symtoms and serum LDH level before treatment and response to previous treatment affected complete response rate, and patients' performance status and response to previous treatment affected progression free survival and overall survival. Toxicities of EPOCH regimen were leukopenia, stomatitis, nausea/vomiting and neurotoxicity, but they were tolerable. There was 1 case of treatment-related death due to sepsis. CONDUSION: EPOCH chemotherapy was safe and effective for the patients with relapsed NHL. However, the results of patients with NHL refractory to previous treatment were so poor that more intensive, novel treatment would be needed for this category of patients.
Cyclophosphamide
;
Disease-Free Survival
;
Doxorubicin*
;
Drug Resistance
;
Drug Therapy*
;
Follow-Up Studies
;
Hodgkin Disease*
;
Humans
;
Leukopenia
;
Lymphoma, Non-Hodgkin
;
Prednisolone
;
Sepsis
;
Stomatitis
;
Vincristine*
5.Antitumor activity of adriamycin and the analogue, THP-adriamycin and epirubicin, against human tumor cell lines.
Weon Seon HONG ; Chang Min KIM ; Myung Shick LEE ; Yoon Koo KANG ; Choon Taek LEE ; You Cheoul KIM ; Jhin Oh LEE ; Tae Woong KANG
Journal of the Korean Cancer Association 1991;23(2):259-265
No abstract available.
Cell Line, Tumor*
;
Doxorubicin*
;
Epirubicin*
;
Humans*
6.A Phase II Trial of Combination Chemotherapy with Cisplatin & Etoposide in Small Cell Lung Cancer.
Eun Mee CHEON ; Hyung Gun KIM ; Tae Young SON ; Young Jin YUH ; Sang Goo LEE ; Choon Taek LEE ; Young Hwan KIM ; Jhin Oh LEE ; Tae Woong KANG
Tuberculosis and Respiratory Diseases 1994;41(6):632-643
BACKGROUND: The objective responses of cisplatin and etoposide (PVP) combination chemotherapy as second-line therapy following CAV was high (40~50%) and, in several reports, PVP yields survival results that are at least as good as those obtained with cyclophosphamide or doxorubicin-based regimens and with less host-related toxicity in chemotherapy-naive patients. We conducted a phase II study to evaluate the effect of a combination of cisplatin and etoposide as a first-line therapy in patients with small cell lung cancer. METHODS: Sixty-one previously untreated small cell lung cancer patients with measurable lesion(s) received cisplatin(30 mg/m2 IV, day 1~3) and etoposide(100 mg/m2 IV, day 1~3). In patients with limited disease, after completion of 6 cycles of PVP chemotherapy, chest and prophylatic brain irradiation was performed in case of complete responder, chest irradiation only in partial responder. RESULTS: 1) Of 55 evaluable patients, 13(24%) had a complete response and 29(53%) had a partial response. 2) The median survival time was 55.8 weeks for all patients(N=55), 61.1 weeks for limited disease(N=31), 51.3 weeks for extensive disease(N=24). 3) The response duration was 29.1 weeks for responders(N=42). 4) There was no significant prognostic factors iufluencing response rates. 5) The toxicity was tolerable and there was no treatment-related deaths. CONCLUSION: The PVP combination chemotherapy as a first-line therapy was effective and well-tolerated in patients with small cell lung cancer.
Brain
;
Cisplatin*
;
Cyclophosphamide
;
Drug Therapy
;
Drug Therapy, Combination*
;
Etoposide*
;
Humans
;
Small Cell Lung Carcinoma*
;
Thorax
7.A case of Thyrotrophin(TSH)-Secreting Giant Pituitary Adenoma: Biochemical Remission with Surgery.
Jong Hyun KIM ; Seung Hoon LEE ; Moon Soo KOH ; Myung Shik LEE ; Jhin Oh LEE ; Tae Woong KANG
Journal of Korean Neurosurgical Society 1991;20(4):224-229
TSH-secreting pituitary adenomas are rare, but have been diagnosed more frequently as radiographic techniques and biochemical assays have improved. These tumors are less easily cured by surgery than are other types of pituitary adenoma because of the large size and invasive features that many attain during the delay to diagnosis. We report a case of TSH-secreting giant pituitary adenoma in which biochemical remission was achieved with surgery.
Diagnosis
;
Pituitary Neoplasms*
8.Transcription of class II MHC gene by interferon-gamma in FRTL-5 cells.
Myung Shik LEE ; Jhin Oh LEE ; Tae Woong KANG ; Je Ho LEE
Journal of Korean Medical Science 1992;7(3):189-192
The intracellular mechanism by which interferon-gamma induces the expression of class II major histocompatibility complex (MHC) antigen in nonlymphoid cells is not clear. The effect of recombinant rat interferon-gamma (IFN-gamma), and cycloheximide on the expression of class II MHC gene was studied using the techniques of immunocytochemical staining and northern blot analysis. IFN-gamma induced de novo transcription of class II MHC gene and class II MHC antigen expression on the cell surface. Cycloheximide did not inhibit IFN-gamma-induced class II MHC antigen expression in a dose-dependent manner indicating translational blockade. These results suggest that IFN-gamma induces class II MHC antigen expression via de novo transcription of class II MHC gene leading to synthesis of new class II MHC molecule.
Animals
;
Cell Line
;
Cycloheximide/pharmacology
;
Gene Expression Regulation/drug effects
;
*Genes, MHC Class II
;
Interferon-gamma/*pharmacology
;
Protein Biosynthesis/drug effects
;
Rats
;
Transcription, Genetic/*drug effects
9.Double Bronchial Lesions Detected by Bronchoscopic Examination.
Chang Hee LEE ; Jong Kil YOON ; Young Im KWAK ; Hyun Kag KIM ; Choon Taek LEE ; Jhin Oh LEE ; Tae Woong KANG
Tuberculosis and Respiratory Diseases 1994;41(3):277-288
OBJECTIVES: Multiple lung cancers and/or precancerous lesions can be developed because many bronchi are exposed to carcinogens simultaneously according to the concept of 'Field Cancerization'. We had performed a careful bronchoscopic examination and analysed the patients of double bronchial lesions who received the separate pathologic evaluation. METHODS: We studied 21 patients of double bronchial lesions among 1855 patients of bronchoscopic examination from April 1990 to December 1993 in Korea Cancer Center Hospital. We classified the patients into three groups(double malignancies of different histology, double malignancies of same histology, and combination of malignant and benign lesions) and analysed the histologic type, location, radiologic findings, and clinical parameters. RESULTS: Among 21 patients, six patients had double malignancies of different histology, eight had double malignancies of same histology, and seven had combination of malignant and benign lesions. Out of 14 double malignant cases, 11 cases are considered as synchronous multiple primary lung cancers. Combination of squamous cell carcinomas was found in 5 cases, combination of small cell carcinoma and squamous cell carcinoma was found in 4 cases. Combination of adenocarcinoma and squamous cell carcinoma and combination of squamous cell carcinoma and poorly differentiated carcinoma were found in 1 case respectively. All patients of synchronous multiple primary lung cancers were male and had long smoking history(average 40 pack years). Among 21 cases of double bronchial lesions, only one lesion could be detected by prebronchoscopic radiologic examination including chest CT in 15 cases. CONCLUSIONS: The presence of double bronchial lesions including multiple primary lung cancers and the limitation of radiologic examination to detect early bronchial lesions encourage us to examine the whole bronchi carefully and to perform pathologic evaluations.
Adenocarcinoma
;
Bronchi
;
Bronchoscopy
;
Carcinogens
;
Carcinoma, Small Cell
;
Carcinoma, Squamous Cell
;
Humans
;
Korea
;
Lung Neoplasms
;
Male
;
Smoke
;
Smoking
;
Tomography, X-Ray Computed
10.Urinary polyamines in patients with gastrointestinal malignancy.
Seo Woon KIM ; Weon Seon HONG ; Bong Seog KIM ; Young Hyun LEE ; Hee Jun CHO ; Chang Min KIM ; Jhin Oh LEE ; Tae Woong KANG ; Seok Il HONG
Journal of the Korean Cancer Association 1991;23(1):76-82
No abstract available.
Humans
;
Polyamines*